DE69925488D1 - Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen - Google Patents

Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen

Info

Publication number
DE69925488D1
DE69925488D1 DE69925488T DE69925488T DE69925488D1 DE 69925488 D1 DE69925488 D1 DE 69925488D1 DE 69925488 T DE69925488 T DE 69925488T DE 69925488 T DE69925488 T DE 69925488T DE 69925488 D1 DE69925488 D1 DE 69925488D1
Authority
DE
Germany
Prior art keywords
pain
medicament
prevention
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69925488T
Other languages
English (en)
Other versions
DE69925488T2 (de
Inventor
S Kelly
S Mcqueen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69925488D1 publication Critical patent/DE69925488D1/de
Publication of DE69925488T2 publication Critical patent/DE69925488T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69925488T 1998-07-06 1999-07-02 Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen Expired - Fee Related DE69925488T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9814640 1998-07-06
GBGB9814640.0A GB9814640D0 (en) 1998-07-06 1998-07-06 New use
PCT/JP1999/003602 WO2000001385A1 (en) 1998-07-06 1999-07-02 Use of fk506 and related macrolides in the manufacture of a medicament for treatment or prevention of pain

Publications (2)

Publication Number Publication Date
DE69925488D1 true DE69925488D1 (de) 2005-06-30
DE69925488T2 DE69925488T2 (de) 2005-11-17

Family

ID=10835037

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925488T Expired - Fee Related DE69925488T2 (de) 1998-07-06 1999-07-02 Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen

Country Status (6)

Country Link
EP (1) EP1093371B1 (de)
JP (1) JP2002519378A (de)
DE (1) DE69925488T2 (de)
ES (1) ES2239446T3 (de)
GB (1) GB9814640D0 (de)
WO (1) WO2000001385A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
AU2004212264B9 (en) * 2003-02-17 2009-11-26 Cipla Limited Pharmaceutical patch
WO2008083169A2 (en) 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
CA2673752A1 (en) 2006-12-27 2008-07-10 The Johns Hopkins University Compositions and methods for stimulating an immune response
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
AU2008282261A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
EP2588123A2 (de) 2010-06-30 2013-05-08 Compugen Ltd. C1orf32 zur behandlung von multipler sklerose, rheumatoider arthritis und anderen autoimmunerkrankungen
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
WO2013155493A1 (en) 2012-04-12 2013-10-17 Yale University Methods of treating inflammatory and autoimmune diseases and disorders
WO2014100439A2 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US20160146806A1 (en) 2013-05-17 2016-05-26 Amplimmune, Inc. Receptors for b7-h4
AU2016316119A1 (en) 2015-09-04 2018-04-19 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
WO2017070676A1 (en) 2015-10-23 2017-04-27 Massachusetts Instittue Of Technology Nanoparticles comprising a metal core surrounded by a monolayer for lymph node targeting
KR102386585B1 (ko) 2016-04-04 2022-04-13 엠씨2 테라퓨틱스 리미티드 타크롤리무스를 포함하는 국소 조성물
ES2982558T3 (es) 2016-09-21 2024-10-16 Nextcure Inc Anticuerpos para Siglec-15 y métodos de uso de los mismos
EP3542788A1 (de) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topische zusammensetzung enthaltend calcipotriol und betamethason dipropionat
AU2019254974A1 (en) * 2018-04-17 2020-11-26 Shanghai Tonglian Pharmaceutical Co., Ltd. Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof
US20210115378A1 (en) 2018-05-09 2021-04-22 Yale University Compositions and systems for ex vivo cell modulation and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859782A (en) * 1986-06-26 1989-08-22 Harbor Branch Oceanographic Institution, Inc. Misakinolide compositions and their derivatives
EP0664130A1 (de) * 1991-10-25 1995-07-26 Senju Pharmaceutical Co., Ltd. Äusserliche Zubereitung zur Behandlung von Hämorhoidalerkrankungen
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
ATE214593T1 (de) * 1994-10-26 2002-04-15 Novartis Erfind Verwalt Gmbh Verwendung eines ungesättigten fettalkohols

Also Published As

Publication number Publication date
JP2002519378A (ja) 2002-07-02
DE69925488T2 (de) 2005-11-17
ES2239446T3 (es) 2005-09-16
EP1093371A1 (de) 2001-04-25
EP1093371B1 (de) 2005-05-25
WO2000001385A1 (en) 2000-01-13
GB9814640D0 (en) 1998-09-02

Similar Documents

Publication Publication Date Title
DE69925488D1 (de) Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
DE69934112D1 (de) Implantierbarer gewebeverschluss und system zur behandlung gastroösophagischen rückflusses
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
ATE280580T1 (de) Verwendung von annexin-modulatoren zur herstellung eines medikaments zur behandlung und/oder vorbeugung von arthritis und arthritischen erkrankungen
DE69822410D1 (de) Modularkatheter zur Abbildung und Behandlung und Montageverfahren
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
ATE210973T1 (de) D2-agonist enthaltendes transdermales therapeutisches system zur behandlung des parkinson-syndroms und verfahren zu seiner herstellung
DE60004974D1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69736585D1 (de) Photokatalytischer formkörper und methode zu seiner herstellung
DE69805438D1 (de) Misch- und ladeöffnung zur medizinischen behandlung
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE69630947D1 (de) Mittel zur schmerzbehandlung
DE60022754D1 (de) Diagnose und behandlung von arrhythmien
DE69934813D1 (de) Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69637449D1 (de) Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen
EP1117395A4 (de) Verbindungen zur behandlung von östrogenabhängigen erkrankungen und deren herstellungs und verwendungsmethoden
DE69635298D1 (de) Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen
ATE431142T1 (de) Arzneimittel zur behandlung und vermeidung neurogener schmerzen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee